Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
peptides
Biotech
Versant's Dayra dawns with $50M Biogen pact
Together, Dayra and Biogen aim to discover and develop oral macrocyclic peptides for immunological diseases.
Gabrielle Masson
Nov 24, 2025 10:28am
Merck links up with Cyprumed in $493M oral peptide deal
Apr 15, 2025 1:11pm
AbbVie acquires oral peptide biotech Nimble for $200M
Dec 13, 2024 10:38am
GemVax's peptide drug fails phase 2a neurodegenerative trial
Oct 29, 2024 11:28am
MBX aims for $136M IPO to take rival to Ascendis into phase 3
Sep 9, 2024 11:59am
MBX files for IPO to take challenger to Ascendis into phase 3
Aug 26, 2024 9:40am
